Overview

Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials

Status:
Completed

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

We aimed to compare efficacy and safety of combination therapy with oral ofloxacin, 400 mg twice daily, plus oral metronidazole, 500 mg twice daily, for 14 days, with moxifloxacin monotherapy, 400 mg once daily, for 14 days

Phase:

Phase 4

Details

Lead Sponsor:

Istanbul Bakirkoy Maternity and Children Diseases Hospital

Treatments:

Anti-Bacterial Agents
Antibiotics, Antitubercular
Fluoroquinolones
Levofloxacin
Metronidazole
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Ofloxacin